1934 - Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)

Presenting Author(s)

• 

  Deidre Wilkins, BSC (she/her/hers)

  Director
  Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
  Gaithersburg, MD, United States

  Slides

Co-Author(s)

• UW

  Ulrika Wählby Hamrén, PhD

  AstraZeneca, Gothenburg, Sweden
  Mölndal, Vastra Gotaland, Sweden
• YC

  Yue Chang, PhD

  AstraZeneca
  Gaithersburg, Maryland, United States
• JD

  Joseph B. Domachowske, MD

  Professor of Pediatrics
  SUNY Upstate Medical University
  Syracuse, New York, United States
• 

  Janet A. Englund, MD

  Professor
  Seattle Children’s Hospital
  Seattle, Washington, United States
• WM

  William J. Muller, MD

  Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University Feinberg School of Medicine
  Chicago, Illinois, United States
• AL

  Amanda Leach, MD

  AstraZeneca
  Gaithersburg, Maryland, United States
• TV

  Tonya L. Villafana, PhD, MPH

  AstraZeneca
  Gaithersburg, Maryland, United States
• EK

  Elizabeth J. Kelly, PhD

  AstraZeneca
  Gaithersburg, Maryland, United States